Description

When mammalian cells are infected by a virus, they release interferons, leading to the expression of various genes, including the RSAD2 gene, which encodes viperin. Viperin is a molecule with extensive antiviral activity, a discovery that has been prominently featured in the prestigious journal Nature. Scientists have found that the Viperin protein can catalyze the production of an extraordinary small biomolecule known as ddhCTP, which inhibits viral replication in vivo. ddhCTP is currently the only known natural antiviral small molecule produced by the body itself. It has gained widespread attention due to its broad-spectrum antiviral activity and lack of toxic side effects. SBS Genetech now offers high-quality ddhCTP for research and applications.

Technical Parameters

• Purity: 98%
• Storage Conditions: -20±5°C
• pH: 8.0
• Molecular Formula: C9H14N3O13P3
• Molecular Weight: 465.14
• Specification: 1ml
• Product Abbreviation: ddhCTP 100mM Solution

Antiviral Mechanism of ddhCTP

In the fierce battlefield of viral replication, the virus acts like a relentless architect, attempting to assemble nucleotides into a genetic material chain. Normally, the virus incorporates CTP as a nucleotide building block to synthesize its genome. However, due to its structural similarity to CTP, ddhCTP can easily be mistaken by the virus as the correct component and incorporated into the genome. This is where the brilliance of ddhCTP lies. Once incorporated, ddhCTP acts as a staunch guardian, preventing subsequent nucleotides from being added to the RNA chain, effectively creating an insurmountable "roadblock" in the viral replication pathway. This chain termination mechanism efficiently halts viral replication.

Specific Experimental Cases:

• Zika Virus Experiment: Researchers added varying concentrations of ddhCTP to a cell culture system containing Zika virus. As the concentration of ddhCTP increased, the replication rate of the Zika virus significantly slowed. At a certain concentration, the release of the virus drastically reduced. For example, in the control group, the quantity of Zika virus in each milliliter of cell culture fluid was 1000 units, whereas in the high concentration ddhCTP experimental group, the virus quantity decreased to less than 100 units, demonstrating a significant inhibitory effect.
• Dengue Virus Experiment: A primer extension experiment revealed that ddhCTP (0, 1, 10, 100, and 300 μM) exhibited concentration-dependent inhibition of Dengue virus (DV) RdRp. At a low concentration of 1 μM, slight inhibition of full-length RNA synthesis was observed; at 100 μM, the production of full-length RNA decreased by approximately 50%; and at a high concentration of 300 μM, the synthesis of full-length RNA was almost completely inhibited.
• West Nile Virus Experiment: In a mouse model infected with West Nile virus, treatment with ddhCTP significantly reduced the viral load in treated mice compared to untreated mice and notably improved their survival rate. Additionally, histopathological examination of the mice showed significantly less organ damage in the ddhCTP-treated group.

Differences Between ddhCTP and Existing Antiviral Drugs

• Unique Mode of Action: Existing antiviral drugs typically function by inhibiting specific viral enzyme activities, preventing the virus from entering cells, or interfering with viral assembly. In contrast, ddhCTP exploits its structural similarity to CTP, deceiving the virus into incorporating it into the genome, thereby blocking the extension of the viral genetic material chain and fundamentally preventing viral replication.
• Specificity and Broad-Spectrum Activity: On one hand, ddhCTP exhibits strong inhibitory effects on multiple members of the Flavivirus genus, such as Zika virus, Dengue virus, West Nile virus, and Hepatitis C virus, demonstrating a certain level of specificity. On the other hand, although its efficacy against members of the Picornaviridae family, such as human rhinovirus and poliovirus, is not significant, this specificity underscores its targeted action and suggests fewer side effects compared to some broad-spectrum antiviral drugs.
• High Safety: Many existing antiviral drugs may cause side effects in the human body, affecting cell growth rate or viability, or even negatively impacting host RNA and DNA polymerases. Experimental results have confirmed that ddhCTP is safe, with no adverse effects on host RNA and DNA polymerases. Overexpression of Viperin and production of ddhCTP also do not negatively impact cell growth rate or viability.

Currently, viperin is the only known human protein capable of producing small molecules that directly inhibit viral replication, and ddhCTP is the only known natural antiviral small molecule produced by the body itself. The artificially synthesized ddhCTP product provided by our company undoubtedly serves as an indispensable tool in the fight against viruses.

SBS Genetech offers a comprehensive range of phosphoramidites on the market. It is recognized as one of the global major leading industry players in Phosphoramidite by third-party market researchers. For more details, please visit Phosphoramidite - Global Forecast 2024-2030.

Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products                                        Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory